L-Tyrozín

Pôsobí na: náladu

L-tyrozín je aminokyselina, ktorá sa používa na produkciu noradrenalínu a dopamínu. Suplementácia pôsobí antistresovo na akútny stres (ktorý zvykne vyčerpať noradrenalín) a môže chrániť pred poruchami pamäte spôsobenými stresom.

Užívanie

L-tyrozín sa zvykne užívať príležitostne v dávke 500-2000 mg, približne 30-60 minút pred akútnym stresom (tým zvykne byť cvičenie). Pozorovania na ľuďoch ukázali, že najlepší antistresový účinok majú dávky 100-150 mg/kg telesnej hmotnosti (9-13 g pre 90 kg človeka), podané 60 minút pred cvičením. Ak užitie vyššej dávky vedie k zažívacím problémom, môže sa dávka rozdeliť na dve dávky, ktoré sa užijú s odstupom cca 30 minút.

Medicínske upozornenie!

Literatúra

  1. Nakashima A, et al. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J Neural Transm. (2009)
  2. Webster D, Wildgoose J. Tyrosine supplementation for phenylketonuria. Cochrane Database Syst Rev. (2010)
  3. Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. Cochrane Database Syst Rev. (2000)
  4. Wurtman RJ, Chou C, Rose CM. Daily rhythm in tyrosine concentration in human plasma: persistence on low-protein diets. Science. (1967)
  5. D’Andrea G, et al. Pathogenesis of migraine: role of neuromodulators. Headache. (2012)
  6. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. (2011)
  7. DiPiro JT, et al. Pharmacotherapy: A pathophysiologic approach. 4th ed.. Stamford, CT: Appleton & Lange. (1999)
  8. van Spronsen FJ, et al. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. Am J Clin Nutr. (2001)
  9. Melmed, S, Williams RH. Williams Textbook of Endocrinology. Saunders Elsevier. (2011)
  10. DiPiro JT, et al. Pharmacotherapy: A pathophysiologic approach. 4th ed.. Stamford, CT: Appleton & Lange. (1999)
  11. Shurtleff D, et al. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav. (1994)
  12. Glaeser BS, et al. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sci. (1979)
  13. Armstrong MD, Stave U. A study of plasma free amino acid levels. II. Normal values for children and adults. Metabolism. (1973)
  14. Ashley DV, et al. Plasma amino acid responses in humans to evening meals of differing nutritional composition. Am J Clin Nutr. (1982)
  15. Elia M, et al. Amino acid metabolism in muscle and in the whole body of man before and after ingestion of a single mixed meal. Am J Clin Nutr. (1989)
  16. Topall G, Laborit H. Brain tyrosine increases after treating with prodrugs: comparison with tyrosine. J Pharm Pharmacol. (1989)
  17. Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. (2007)
  18. Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. Psychother Psychosom. (1993)
  19. Yeghiayan SK, et al. Tyrosine improves behavioral and neurochemical deficits caused by cold exposure. Physiol Behav. (2001)
  20. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation.
  21. Neri DF, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med. (1995)
  22. Lehnert H, et al. Neurochemical and behavioral consequences of acute, uncontrollable stress: effects of dietary tyrosine. Brain Res. (1984)
  23. Irwin J, Suissa A, Anisman H. Differential effects of inescapable shock on escape performance and discrimination learning in a water escape task. J Exp Psychol Anim Behav Process. (1980)
  24. Weiss JM. Effects of coping behavior in different warning signal conditions on stress pathology in rats. J Comp Physiol Psychol. (1971)
  25. Brady K, Brown JW, Thurmond JB. Behavioral and neurochemical effects of dietary tyrosine in young and aged mice following cold-swim stress. Pharmacol Biochem Behav. (1980)
  26. Behavioral Depression Produced by An Uncontrollable Stressor: Relationship to Norepinephrine, Dopamine, and Serotonin Levels in Various Regions of Rat Brain.
  27. Tyrosine Pretreatment Reverses HypothermiaInduced Behavioral Depression.
  28. Tyrosine and Stress: Human and Animal Studies.
  29. Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull. (1989)
  30. Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull. (1994)
  31. Dollins AB, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav. (1995)
  32. Deijen JB, et al. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Res Bull. (1999)
  33. Jodko K, Litwinienko G. Oxidative stress in the neurodegenerative diseases–potential antioxidant activity of catecholamines. Postepy Biochem. (2010)
  34. Yamori Y, et al. The hypotensive effect of centrally administered tyrosine. Eur J Pharmacol. (1980)
  35. Tyrosine administration reduces blood pressure and enhances brain norepinephrine release in spontaneously hypertensive rats.
  36. Meeusen R, Watson P, Dvorak J. The brain and fatigue: new opportunities for nutritional interventions. J Sports Sci. (2006)
  37. Magnusson I, et al. N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans. Metabolism. (1989)
  38. Hoffer LJ, et al. N-acetyl-L-tyrosine as a tyrosine source in adult parenteral nutrition. JPEN J Parenter Enteral Nutr. (2003)
  39. Shibui Y, et al. 13-week repeated dose toxicity study of l-tyrosine in rats by daily oral administration. Food Chem Toxicol. (2016)
  40. D’Andrea G, et al. The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia. (2013)
  41. CFR-Code of Federal Regulations Title 21.
  42. Wood DR, Reimherr FW, Wender PH. Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol Bull. (1985)
  43. Reimherr FW, et al. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. Am J Psychiatry. (1987)
  44. Jongkees BJ, et al. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands–A review. J Psychiatr Res. (2015)
  45. Lewis SA , Lyon ICT, Elliott RB. Outcome of pregnancy in the rat with mild hyperphenylalaninaemia and hypertyrosinaemia: Implications for the management of “human maternal PKU. J Inherit Metab Dis. (1985)
  46. Thomas JR, et al. Tyrosine improves working memory in a multitasking environment. Pharmacol Biochem Behav. (1999)
  47. Palinkas LA, et al. Psychoneuroendocrine effects of combined thyroxine and triiodothyronine versus tyrosine during prolonged Antarctic residence. Int J Circumpolar Health. (2007)
  48. Deutsch SI, et al. L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin Neuropharmacol. (1994)
  49. Ryan MM, et al. Dietary L-tyrosine supplementation in nemaline myopathy. J Child Neurol. (2008)
  50. Meyer JS, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer’s disease. J Am Geriatr Soc. (1977)